Trials / Unknown
UnknownNCT06116240
A Clinical Trial of TQB2450 Injection Combined With AL2846 Capsules in Patients With Advanced Solid Tumors
A Phase Ib Clinical Trial to Evaluate the Safety and Efficacy of TQB2450 Injection Combined With AL2846 Capsules in Patients With Advanced Solid Tumors
- Status
- Unknown
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 135 (estimated)
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
This is a Phase Ib clinical trial to evaluate the safety and efficacy of TQB2450 injection combined with AL2846 capsules in patients with advanced solid tumors.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | TQB2450 injection | TQB2450 is a humanized monoclonal antibody targeting programmed death ligand-1 (PD-L1). |
| DRUG | AL2846 capsule | AL2846 is a multi-targeted tyrosine kinase receptor inhibitor |
| DRUG | Pemetrexed disodium for injection | Pemetrexed disodium is a multi-target antifolate antineoplastic drug. |
| DRUG | Cisplatin injection | Cisplatin is a chemotherapy drug. |
Timeline
- Start date
- 2022-09-02
- Primary completion
- 2023-12-01
- Completion
- 2023-12-01
- First posted
- 2023-11-03
- Last updated
- 2023-11-03
Locations
12 sites across 1 country: China
Source: ClinicalTrials.gov record NCT06116240. Inclusion in this directory is not an endorsement.